博济医药
(300404)
| 流通市值：23.30亿 | | | 总市值：32.11亿 |
| 流通股本：2.78亿 | | | 总股本：3.83亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 138,861,747.84 | 742,019,124.54 | 556,148,773.73 | 341,390,828.56 |
| 营业收入 | 138,861,747.84 | 742,019,124.54 | 556,148,773.73 | 341,390,828.56 |
| 二、营业总成本 | 133,525,582.85 | 711,635,085.64 | 519,937,507.73 | 318,142,631.73 |
| 营业成本 | 96,368,429.87 | 516,629,157.81 | 377,140,098.56 | 230,057,272.34 |
| 税金及附加 | 1,206,376.71 | 6,914,185.11 | 5,305,161.39 | 3,379,649.52 |
| 销售费用 | 11,782,325.58 | 53,809,106 | 38,727,578.79 | 23,456,898.94 |
| 管理费用 | 14,529,635.19 | 70,633,027.32 | 53,418,372.24 | 34,003,454.81 |
| 研发费用 | 9,289,734.47 | 62,593,951.61 | 44,450,607.56 | 26,820,863.07 |
| 财务费用 | 349,081.03 | 1,055,657.79 | 895,689.19 | 424,493.05 |
| 其中:利息费用 | 509,095.34 | 3,186,407.41 | 2,560,897.37 | 1,474,917.07 |
| 其中:利息收入 | 205,526.25 | 2,300,564.7 | 1,799,050.78 | 1,138,380.44 |
| 加:公允价值变动收益 | 490,581.85 | 1,058,690.69 | 980,609.38 | 554,634.23 |
| 加:投资收益 | 61,231.81 | 1,979,446.48 | 1,481,998.22 | 1,378,132.49 |
| 资产处置收益 | - | -213,678.75 | - | - |
| 资产减值损失(新) | -1,199,977.4 | -6,349,010.26 | -3,751,485.06 | -1,315,731.08 |
| 信用减值损失(新) | -3,344,588.25 | -17,543,157.35 | -11,882,335.6 | -8,498,561.3 |
| 其他收益 | 2,560,044.7 | 9,270,391.91 | 8,184,065.05 | 4,104,516.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,903,457.7 | 18,586,721.62 | 31,224,117.99 | 19,471,187.49 |
| 加:营业外收入 | 11.85 | 44,805.46 | 45,041.32 | 44,930.78 |
| 减:营业外支出 | 60,381.7 | 212,030.13 | 105,911.39 | 45,275.77 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,843,087.85 | 18,419,496.95 | 31,163,247.92 | 19,470,842.5 |
| 减:所得税费用 | -837,653.21 | -12,237,970.27 | -14,198,504.19 | -11,414,448.97 |
| 六、净利润 | 4,680,741.06 | 30,657,467.22 | 45,361,752.11 | 30,885,291.47 |
| 持续经营净利润 | 4,680,741.06 | 30,657,467.22 | 45,361,752.11 | 30,885,291.47 |
| 归属于母公司股东的净利润 | 3,900,579.72 | 28,776,806.52 | 43,277,754.83 | 30,135,149.57 |
| 少数股东损益 | 780,161.34 | 1,880,660.7 | 2,083,997.28 | 750,141.9 |
| (一)基本每股收益 | 0.01 | 0.08 | 0.11 | 0.08 |
| (二)稀释每股收益 | 0.01 | 0.08 | 0.11 | 0.08 |
| 八、其他综合收益 | -82,948.74 | 519,743.78 | -369,497.05 | 136,044.61 |
| 归属于母公司股东的其他综合收益 | -82,366.48 | 513,436.7 | -365,486.64 | 132,935.5 |
| 九、综合收益总额 | 4,597,792.32 | 31,177,211 | 44,992,255.06 | 31,021,336.08 |
| 归属于母公司股东的综合收益总额 | 3,818,213.24 | 29,290,243.22 | 42,912,268.19 | 30,268,085.07 |
| 归属于少数股东的综合收益总额 | 779,579.08 | 1,886,967.78 | 2,079,986.87 | 753,251.01 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |